Back to top
more

Aphria Inc. (APHA)

(Delayed Data from NYSE)

$6.94 USD

6.94
5,631,062

-0.19 (-2.66%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid

by Zacks Equity Research

Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.

Here's Why You Should Invest in OPKO Health (OPK) Stock Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain traction from solid prospects in RAYALDEE and BioReference platforms.

Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Inogen (INGN) stock, thanks to solid prospects.

Here's Why You Should Hold on to Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem

by Zacks Equity Research

NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.

IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis

by Zacks Equity Research

IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.

Varian (VAR) Unveils New Features for Noona Software

by Zacks Equity Research

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Baxter Receives CE Marking for Evo IQ Syringe Infusion System

by Zacks Equity Research

Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.

Henry Schein Sales Drop on Coronavirus Woes, Costs Rise

by Zacks Equity Research

Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

Medtronic Gets FDA Nod for Guardian CGM's Android Version

by Zacks Equity Research

Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

Here's Why You Should Hold on to Edwards Lifesciences for Now

by Zacks Equity Research

Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.

Cerner and Hospital IQ Partner to Boost Clinical Awareness

by Zacks Equity Research

Cerner (CERN) partners with Hospital IQ to help health systems with predictive analytics to enhance clinical and operational awareness.

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Zacks.com headshot

Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks.com

Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.

McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.

Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty

by Zacks Equity Research

Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.

Veeva Systems Boosts Product Portfolio With New Application

by Zacks Equity Research

Veeva Systems (VEEV) announces a new application called MyVeeva to enable patient-centric clinical trials.

Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.

Here's Why You Should Retain Merit Medical (MMSI) for Now

by Zacks Equity Research

Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.

ResMed (RMD) Launches Digital Tool for Remote Mask Selection

by Zacks Equity Research

Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.

    Neogen (NEOG) Introduces Upgraded Igenity Beef Genomic Profile

    by Zacks Equity Research

    Neogen (NEOG) looks to provide better technology and information to commercial beef producers to take better decisions for their profitability.